• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

鉴定与胶质瘤临床预后相关的间质相关特征。

Identification of a mesenchymal-related signature associated with clinical prognosis in glioma.

机构信息

Department of Neurosurgery, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.

Cerebral Vascular Disease Research Center, Anhui Medical University, Hefei 230601, China.

出版信息

Aging (Albany NY). 2021 Apr 19;13(9):12431-12455. doi: 10.18632/aging.202886.

DOI:10.18632/aging.202886
PMID:33875619
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8148476/
Abstract

Malignant glioma with a mesenchymal (MES) signature is characterized by shorter survival time due to aggressive dissemination and resistance to chemoradiotherapy. Here, this study used the TCGA database as the training set and the CGGA database as the testing set. Consensus clustering was performed on the two data sets, and it was found that two groups had distinguished prognostic and molecular features. Cox analysis and Lasso regression analysis were used to construct MES signature-based risk score model of glioma. Our results show that MES signature-based risk score model can be used to assess the prognosis of glioma. Three methods (ROC curve analyses, univariate Cox regression analysis, multivariate Cox regression analysis) were used to investigate the prognostic role of texture parameters. The result showed that the MES-related gene signature was proved to be an independent prognostic factor for glioma. Furthermore, functional analysis of the gene related to the risk signature showed that the genes sets were closely related to the malignant process of tumors. Finally, FCGR2A and EHD2 were selected for functional verification. Silencing these two genes inhibited the proliferation, migration and invasion of gliomas and reduced the expression of mesenchymal marker genes. Collectively, MES-related risk signature seems to provide a novel target for predicting the prognosis and treatment of glioma.

摘要

具有间充质（MES）特征的恶性神经胶质瘤由于侵袭性扩散和对放化疗的耐药性，导致生存时间更短。在此，本研究使用 TCGA 数据库作为训练集和 CGGA 数据库作为测试集。对这两个数据集进行共识聚类分析，发现两组具有明显不同的预后和分子特征。采用 Cox 分析和 Lasso 回归分析构建基于 MES 特征的神经胶质瘤风险评分模型。我们的研究结果表明，基于 MES 特征的风险评分模型可用于评估神经胶质瘤的预后。采用三种方法（ROC 曲线分析、单因素 Cox 回归分析、多因素 Cox 回归分析）探讨纹理参数的预后作用。结果表明，与 MES 相关的基因特征被证明是神经胶质瘤的独立预后因素。此外，对风险特征相关基因的功能分析表明，基因集与肿瘤的恶性进程密切相关。最后，选择 FCGR2A 和 EHD2 进行功能验证。沉默这两个基因可抑制神经胶质瘤的增殖、迁移和侵袭，并降低间充质标志物基因的表达。综上所述，与 MES 相关的风险特征似乎为预测神经胶质瘤的预后和治疗提供了新的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/71c9c81e80bb/aging-13-202886-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/f10ab07b3a71/aging-13-202886-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/8332d2031824/aging-13-202886-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/b1c13729aef4/aging-13-202886-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/cd9885a9e1c3/aging-13-202886-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/27b1ddff2c2d/aging-13-202886-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/16d68933be5f/aging-13-202886-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/6d882b4aa862/aging-13-202886-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/9d9a08c1be0b/aging-13-202886-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/71c9c81e80bb/aging-13-202886-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/f10ab07b3a71/aging-13-202886-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/8332d2031824/aging-13-202886-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/b1c13729aef4/aging-13-202886-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/cd9885a9e1c3/aging-13-202886-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/27b1ddff2c2d/aging-13-202886-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/16d68933be5f/aging-13-202886-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/6d882b4aa862/aging-13-202886-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/9d9a08c1be0b/aging-13-202886-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/096d/8148476/71c9c81e80bb/aging-13-202886-g009.jpg

相似文献

1
Identification of a mesenchymal-related signature associated with clinical prognosis in glioma.鉴定与胶质瘤临床预后相关的间质相关特征。
Aging (Albany NY). 2021 Apr 19;13(9):12431-12455. doi: 10.18632/aging.202886.
2
Identification of an endoplasmic reticulum stress-related signature associated with clinical prognosis and immune therapy in glioma.鉴定与神经胶质瘤临床预后和免疫治疗相关的内质网应激相关特征。
BMC Neurol. 2022 May 25;22(1):192. doi: 10.1186/s12883-022-02709-y.
3
Amino acid metabolism-related gene expression-based risk signature can better predict overall survival for glioma.基于氨基酸代谢相关基因表达的风险特征可更好地预测胶质瘤患者的总生存期。
Cancer Sci. 2019 Jan;110(1):321-333. doi: 10.1111/cas.13878. Epub 2018 Dec 17.
4
Development and Validation of an Mesenchymal-Related Long Non-Coding RNA Prognostic Model in Glioma.胶质瘤中间充质相关长链非编码RNA预后模型的构建与验证
Front Oncol. 2021 Sep 3;11:726745. doi: 10.3389/fonc.2021.726745. eCollection 2021.
5
An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.预测低级别胶质瘤预后的免疫相关标志物。
Front Immunol. 2020 Dec 8;11:603341. doi: 10.3389/fimmu.2020.603341. eCollection 2020.
6
Comprehensive profiling identifies a novel signature with robust predictive value and reveals the potential drug resistance mechanism in glioma.全面分析确定了一个具有强大预测价值的新型标志物，并揭示了胶质瘤潜在的耐药机制。
Cell Commun Signal. 2020 Jan 6;18(1):2. doi: 10.1186/s12964-019-0492-6.
7
Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Prognosis, and Immune Phenotype of Glioma.生物信息学分析鉴定出脂肪酸代谢相关基因风险-signature 与胶质瘤的恶性程度、预后和免疫表型相关。
Dis Markers. 2019 Dec 4;2019:3917040. doi: 10.1155/2019/3917040. eCollection 2019.
8
Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling.基于mRNA表达谱的九基因特征在胶质瘤患者中的预后价值
CNS Neurosci Ther. 2014 Feb;20(2):112-8. doi: 10.1111/cns.12171. Epub 2013 Nov 27.
9
Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.鉴定一种与五个B细胞相关基因的预后和预测特征，用于具有免疫抑制亚型偏好的晚期胶质瘤患者。
Oncotarget. 2016 Nov 8;7(45):73971-73983. doi: 10.18632/oncotarget.12605.
10
A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.核转运相关基因特征与 IDH 突变和 1p/19q 联合缺失可更好地预测胶质瘤患者的预后。
BMC Cancer. 2020 Nov 9;20(1):1072. doi: 10.1186/s12885-020-07552-3.

引用本文的文献

1
Overexpression of LSR suppresses glioma proliferation and invasion via regulating FOXO3a.LSR的过表达通过调节FOXO3a抑制胶质瘤的增殖和侵袭。
J Neurooncol. 2025 May;173(1):179-192. doi: 10.1007/s11060-025-04976-4. Epub 2025 Feb 24.
2
EHD2 overexpression promotes tumorigenesis and metastasis in triple-negative breast cancer by regulating store-operated calcium entry.EHD2 过表达通过调节钙库操纵性钙内流促进三阴性乳腺癌的发生和转移。
Elife. 2023 Jan 10;12:e81288. doi: 10.7554/eLife.81288.
3
Identification of an endoplasmic reticulum stress-related signature associated with clinical prognosis and immune therapy in glioma.

本文引用的文献

1
Novel Treatment Strategies for Glioblastoma.胶质母细胞瘤的新型治疗策略
Cancers (Basel). 2020 Oct 8;12(10):2883. doi: 10.3390/cancers12102883.
2
N6-Methylandenosine-Related lncRNAs Are Potential Biomarkers for Predicting the Overall Survival of Lower-Grade Glioma Patients.N6-甲基腺苷相关长链非编码RNA是预测低级别胶质瘤患者总生存期的潜在生物标志物。
Front Cell Dev Biol. 2020 Jul 23;8:642. doi: 10.3389/fcell.2020.00642. eCollection 2020.
3
An Immune-Related lncRNA Signature to Predict Survival In Glioma Patients.免疫相关长链非编码 RNA 标志物预测胶质瘤患者的生存情况。
鉴定与神经胶质瘤临床预后和免疫治疗相关的内质网应激相关特征。
BMC Neurol. 2022 May 25;22(1):192. doi: 10.1186/s12883-022-02709-y.
4
Construction of Molecular Subtypes and Related Prognostic and Immune Response Models Based on M2 Macrophages in Glioblastoma.基于胶质母细胞瘤中M2巨噬细胞构建分子亚型及相关预后和免疫反应模型
Int J Gen Med. 2022 Jan 26;15:913-926. doi: 10.2147/IJGM.S343152. eCollection 2022.
5
Comprehensive transcriptomic characterization reveals core genes and module associated with immunological changes via 1619 samples of brain glioma.综合转录组特征分析揭示了 1619 例脑胶质瘤样本中与免疫变化相关的核心基因和模块。
Cell Death Dis. 2021 Dec 8;12(12):1140. doi: 10.1038/s41419-021-04427-8.
Cell Mol Neurobiol. 2021 Mar;41(2):365-375. doi: 10.1007/s10571-020-00857-8. Epub 2020 May 14.
4
Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.通过肿瘤微环境的转录谱分析，改善胶质母细胞瘤的预后，超越分子亚型分类。
Mol Oncol. 2020 May;14(5):1016-1027. doi: 10.1002/1878-0261.12668. Epub 2020 Apr 4.
5
Super-enhancers: A new frontier for glioma treatment.超级增强子：胶质瘤治疗的新前沿。
Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188353. doi: 10.1016/j.bbcan.2020.188353. Epub 2020 Feb 26.
6
Immune landscapes associated with different glioblastoma molecular subtypes.与不同胶质母细胞瘤分子亚型相关的免疫图谱。
Acta Neuropathol Commun. 2019 Nov 29;7(1):203. doi: 10.1186/s40478-019-0803-6.
7
Mesenchymal stem cells promote healing of nonsteroidal anti-inflammatory drug-related peptic ulcer through paracrine actions in pigs.间质干细胞通过旁分泌作用促进猪非甾体抗炎药相关消化性溃疡的愈合。
Sci Transl Med. 2019 Oct 30;11(516). doi: 10.1126/scitranslmed.aat7455.
8
Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics.当前和未来的胶质母细胞瘤诊断和预后趋势：从分子生物学到蛋白质组学。
Cells. 2019 Aug 9;8(8):863. doi: 10.3390/cells8080863.
9
Mesenchymal transition and increased therapy resistance of glioblastoma cells is related to astrocyte reactivity.间质转化和胶质母细胞瘤细胞对治疗的抵抗力增加与星形胶质细胞反应性有关。
J Pathol. 2019 Nov;249(3):295-307. doi: 10.1002/path.5317. Epub 2019 Aug 31.
10
Targeting of replicating CD133 and OCT4/SOX2 expressing glioma stem cells selects a cell population that reinitiates tumors upon release of therapeutic pressure.靶向复制的 CD133 和 OCT4/SOX2 表达的神经胶质瘤干细胞选择了一个细胞群体，该群体在治疗压力释放后重新启动肿瘤。
Sci Rep. 2019 Jul 2;9(1):9549. doi: 10.1038/s41598-019-46014-0.